Rocket Pharmaceuticals Stock Performance
| RCKT Stock | USD 14.20 0.09 0.64% |
The company holds a Beta of 1.9, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rocket Pharmaceuticals will likely underperform. At this point, Rocket Pharmaceuticals has a negative expected return of -0.3%. Please make sure to check Rocket Pharmaceuticals' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Rocket Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rocket Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's forward-looking signals remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.64 | Five Day Return 11.64 | Year To Date Return (51.86) | Ten Year Return (40.83) | All Time Return (40.83) |
Last Split Factor 1:4 | Dividend Date 2018-01-05 | Last Split Date 2018-01-05 |
1 | Insider Trading | 09/05/2024 |
2 | Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3 | 09/06/2024 |
3 | Disposition of 917 shares by Militello John of Rocket Pharmaceuticals at 16.625 subject to Rule 16b-3 | 10/31/2024 |
4 | Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress | 11/07/2024 |
5 | Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breakin... | 11/12/2024 |
6 | RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd | 11/14/2024 |
7 | Rocket Pharmaceuticals Earns Buy Rating from Chardan Capital | 11/15/2024 |
8 | Disposition of 1175 shares by Wilson Martin of Rocket Pharmaceuticals at 13.054 subject to Rule 16b-3 | 11/21/2024 |
9 | Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference | 11/26/2024 |
| Begin Period Cash Flow | 141.9 M |
Rocket |
Rocket Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,800 in Rocket Pharmaceuticals on August 31, 2024 and sell it today you would lose (380.00) from holding Rocket Pharmaceuticals or give up 21.11% of portfolio value over 90 days. Rocket Pharmaceuticals is currently does not generate positive expected returns and assumes 3.9102% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Rocket, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rocket Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rocket Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rocket Pharmaceuticals, and traders can use it to determine the average amount a Rocket Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0772
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RCKT |
Estimated Market Risk
| 3.91 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rocket Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rocket Pharmaceuticals by adding Rocket Pharmaceuticals to a well-diversified portfolio.
Rocket Pharmaceuticals Fundamentals Growth
Rocket Stock prices reflect investors' perceptions of the future prospects and financial health of Rocket Pharmaceuticals, and Rocket Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rocket Stock performance.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 1.08 B | ||||
| Shares Outstanding | 91.16 M | ||||
| Price To Book | 3.93 X | ||||
| EBITDA | (236.62 M) | ||||
| Net Income | (245.59 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.04 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (194.92 M) | ||||
| Earnings Per Share | (2.73) X | ||||
| Market Capitalization | 1.29 B | ||||
| Total Asset | 566.34 M | ||||
| Retained Earnings | (959.37 M) | ||||
| Working Capital | 329.72 M | ||||
About Rocket Pharmaceuticals Performance
Assessing Rocket Pharmaceuticals' fundamental ratios provides investors with valuable insights into Rocket Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rocket Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.43) | (0.46) | |
| Return On Equity | (0.50) | (0.52) |
Things to note about Rocket Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rocket Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rocket Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rocket Pharmaceuticals generated a negative expected return over the last 90 days | |
| Rocket Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (245.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rocket Pharmaceuticals currently holds about 321.37 M in cash with (194.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference |
- Analyzing Rocket Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rocket Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rocket Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rocket Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rocket Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rocket Pharmaceuticals' stock. These opinions can provide insight into Rocket Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.